# A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

> **NCT04002310** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** BI 754132

## Key facts

- **NCT ID:** NCT04002310
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-26
- **Primary completion:** 2022-08-09
- **Final completion:** 2022-08-09
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The trial was discontinued in the interests of patients considering benefit/risk balance.
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04002310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04002310, "A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04002310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*